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A 72-year-old female nonsmoker presented with drycough and progressive exertional dyspnea for 4
months. Chest radiography disclosed multiple nodular
opacities in bilateral lung fields and right pleural effusion.
A computed tomography (CT) of the chest after the drain-
age of pleural effusion (Figure 1A) showed an irregular
mass at right upper lung. Serum carcinoembryonic antigen
(CEA) level was 442.1 ng/ml. The cytology of echo-
guided lung aspiration and right pleural effusion both
yielded adenocarcinoma. The bronchial biopsy specimens
showed neoplastic glands with immunoreactivity to thy-
roid transcription factor-1 protein and cytokeratin 7. Stage
IV lung adenocarcinoma with metastasis to brain and bone
was diagnosed. A repeated chest CT (Figure 1B) 92 days
after gefitinib treatment showed dramatic shrinkage of
right upper lobe mass. The CEA declined to 87.6 ng/ml
196 days after gefitinib treatment. The RNA extracted
from cancer cells of echo-guided lung aspiration at the
diagnosis of lung cancer was assessed for epidermal
growth factor receptor (EGFR) mutation and echinoderm
microtubule-associated protein-like 4 (EML4)-anaplastic
lymphoma kinase (ALK) fusion by reverse transcription-
polymerase chain reaction and sequencing assays as pre-
viously described.1,2 Besides a variant 1 of EML4-ALK
translocation, a mutant form of EGFR del 2235–2249 (del
E746-A750) in exon 19 was identified (Figure 2). After
232 days of gefitinib treatment, the patient showed disease
progression.
The trend of lung cancer treatment has been toward
personalized therapy. Identifying molecular genetic marker to
guide treatment has been successfully demonstrated in the
treatment of lung adenocarcinoma in East Asia. Patients with
the characteristics of being female, nonsmoker or former light
smoker, previously untreated, and advanced stage, and espe-
cially the presence of mutation of the EGFR gene, benefited
much from EGFR tyrosine kinase inhibitor (TKI) compared
with conventional cytotoxic chemotherapy.3
Recently, the EML4-ALK, a fusion gene first de-
scribed in 2007, possesses oncogenic activity that can be
blocked by ALK kinase inhibitor and represents a new
therapeutic target in non-small cell lung cancer (NSCLC).
EML4-ALK has been identified in 0.4 to 13.5% of uns-
elected NSCLC patients.4 This subset of patients are often
light or never smokers and mostly with adenocarcinoma,4
similar to those with EGFR mutations. The EML4-ALK
fusions are almost in mutual exclusion to EGFRmutation,4 with
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FIGURE 1. Compared with the initial computed tomogra-
phy (CT) of thorax (A) and the repeated CT 92 days after
gefitinib treatment (B), dramatic shrinkage of right upper
lobe mass was shown.
Journal of Thoracic Oncology • Volume 5, Number 12, December 2010 2039
rare exceptions.5 EGFR TKI treatment in patients with EML4-
ALK-positive tumor was not beneficial.6 In murine model with
EML4-ALK NSCLC, erlotinib was also not effective.5 In our
case, a favorable response was observed both in image and CEA
level after gefitinib treatment. To our knowledge, this is the first
case report of initial dramatic response to EGFR TKI in a lung
adenocarcinoma patient harboring both EML4-ALK fusion and
EGFR mutation. Because the ALK inhibitor was not on the
market yet, we did not know the response of ALK inhibitor in
this patient.
In conclusion, careful survey of the EGFR mutation
status is still necessary even when facing patients with
NSCLC harboring EML4-ALK fusion gene. Further study is
warranted to clarify the biologic feature and the optimal
treatment in this subset of patients with coexisting EML4-
ALK fusion and EGFR mutation.
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FIGURE 2. A mutant form of epidermal growth
factor receptor (EGFR) del 2235–2249 (del E746-
A750) in exon 19 (upper panel) and a variant 1 of
echinoderm microtubule-associated protein-like 4
(EML4)-anaplastic lymphoma kinase (ALK) translo-
cation (lower panel) were identified by reverse
transcription-polymerase chain reaction and se-
quencing assays.
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